British pharmaceutical company GSK has announced encouraging early-stage trial results for Mocertatug Rezetecan (known as Mo-Rez), a cancer drug targeting gynaecological tumours. The treatment shrank or eliminated tumours in 62% of ovarian cancer patients and 67% of those with endometrial cancer whose conditions had not responded to chemotherapy, with relatively few patients stopping due to side-effects. Based on these results and supporting data from a separate Chinese trial, GSK plans to move directly to late-stage global studies, with the drug projected to become a blockbuster treatment generating over £2 billion in annual peak sales.